Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345575 | 1.00 | CRHR1 (0.41) | CRHR1SCN4ACCR4 | |
| SCHEMBL7707751 | 0.71 | CRHR1 (0.73) | CRHR1 | |
| SCHEMBL6340859 | 0.70 | CRHR1 (0.56) | CRHR1 | |
| SCHEMBL7501629 | 0.60 | SCN4A (0.58) | SCN4A | |
| SCHEMBL6726554 | 0.60 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL15747657 | 0.58 | CCNC (0.49) | — | |
| SCHEMBL5246749 | 0.58 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5250469 | 0.58 | CRHR1 (0.77) | CRHR1 | |
| SCHEMBL29640018 | 0.58 | ROCK2 (0.59) | — | |
| SCHEMBL6722252 | 0.58 | CRHR1 (1.00) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974808-B2 | CRF receptor antagonists and methods relating thereto | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20020049207-A1 | CRF receptor antagonists and methods relating thereto | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049207-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | CRHR1 1/4885SCN4A 2532/4885CCR4 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.